Cost-Effectiveness/ Cost-Benefit Analysis of Newborn Screening (NBS) for Severe Combined Immune Deficiency (SCID) in Washington State

Date: May 2016

This closed-access study evaluated the expected cost-effectiveness and net benefit of the recent implementation of newborn screening (NBS) for severe combined immunodeficiency (SCID) in Washington State.